Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 10:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 850 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Cancer Recurrent Clear all
Completed Phase 2 Interventional

Paclitaxel Plus Monoclonal Antibody Therapy in Treating Women With Recurrent or Metastatic Breast Cancer

NCT00003539
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, paclitaxel
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 20, 2026, 10:36 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer

NCT00368875
View directory record Official record
Conditions
Male Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
vorinostat, paclitaxel, bevacizumab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced Oct 20, 2026, 10:36 PM EDT
Completed Phase 2 Interventional

High-Dose Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer

NCT00003392
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, carboplatin, cyclophosphamide, melphalan, paclitaxel, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
14
States / cities
La Jolla, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 20, 2026, 10:36 PM EDT
Completed Phase 3 Interventional

Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer

NCT00002836
View directory record Official record
Conditions
Breast Cancer
Interventions
Filgrastim (G-CSF), Carmustine, Cisplatin, Cyclophosphamide (CTX), Etoposide, Thiotepa, Peripheral Blood Stem Cell Transplantation
Biological · Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Oct 20, 2026, 10:36 PM EDT
Completed Not applicable Interventional

Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

NCT00079222
View directory record Official record
Conditions
Cancer
Interventions
itraconazole, voriconazole
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
12 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 20, 2026, 10:36 PM EDT
Active, not recruiting Phase 1 Interventional

Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer

NCT02157051
View directory record Official record
Conditions
HER2 Negative Breast Carcinoma, Recurrent Breast Carcinoma, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer
Interventions
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 20, 2026, 10:36 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca

NCT02041429
View directory record Official record
Conditions
Recurrent Breast Cancer, Metastatic Breast Cancer
Interventions
Ruxolitinib, Paclitaxel
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Oct 20, 2026, 10:36 PM EDT
Completed Phase 2 Interventional

Oral Paclitaxel Efficacy Safety and PK in Recurrent and Metastatic Breast Cancer

NCT03326102
View directory record Official record
Conditions
Recurrent or Metastatic Breast Cancer
Interventions
DHP107, IV Paclitaxel
Drug
Lead sponsor
Daehwa Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Boca Raton, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2024 · Synced Oct 20, 2026, 10:36 PM EDT
Completed Phase 2 Interventional Results available

Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer

NCT00232505
View directory record Official record
Conditions
Breast Cancer
Interventions
cetuximab, carboplatin
Biological · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
14
States / cities
Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Oct 20, 2026, 10:36 PM EDT
Completed Not applicable Interventional Results available

Cryoablation of Low Risk Small Breast Cancer- ICE3 Trial

NCT02200705
View directory record Official record
Conditions
Breast Cancer
Interventions
Ice-Sense3TM/ ProSenseTM
Device
Lead sponsor
IceCure Medical Ltd.
Industry
Eligibility
50 Years and older · Female only
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
19
States / cities
Glendale, Arizona • Santa Ana, California • Trumbull, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 20, 2026, 10:36 PM EDT
Suspended Phase 3 Interventional Results available

Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer

NCT02037529
View directory record Official record
Conditions
Breast Adenocarcinoma, HER2/Neu Negative, Invasive Breast Carcinoma, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Eribulin Mesylate, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment
Drug · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
39
States / cities
Scottsdale, Arizona • Newark, Delaware • Washington D.C., District of Columbia + 33 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 20, 2026, 10:36 PM EDT
Completed Phase 2 Interventional Results available

Mini-Allogeneic Peripheral Blood Progenitor Cell Transplantation For Recurrent or Metastatic Breast Cancer

NCT00429572
View directory record Official record
Conditions
Breast Cancer
Interventions
Fludarabine, Melphalan, Stem Cell Infusion
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 60 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Oct 20, 2026, 10:36 PM EDT
Completed Phase 2 Interventional

Irofulven in Treating Patients With Metastatic Breast Cancer

NCT00003796
View directory record Official record
Conditions
Breast Cancer
Interventions
irofulven
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 20, 2026, 10:36 PM EDT
Completed Not applicable Interventional Results available

Radiation Therapy in Treating Patients With Recurrent Breast Cancer

NCT00945061
View directory record Official record
Conditions
Breast Cancer
Interventions
intracavitary balloon brachytherapy, intraoperative radiation therapy
Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
3
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Oct 20, 2026, 10:36 PM EDT
Completed Phase 1 Interventional

Ketogenic Diet and Chemotherapy in Affecting Recurrence in Patients With Stage IV Breast Cancer

NCT03535701
View directory record Official record
Conditions
Stage IV Breast Cancer AJCC v6 and v7
Interventions
Dietary Intervention, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration
Dietary Supplement · Other · Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 8, 2025 · Synced Oct 20, 2026, 10:36 PM EDT
Suspended No phase listed Observational

CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2

NCT03253575
View directory record Official record
Conditions
Adult Solid Tumor
Interventions
CANscript
Diagnostic Test
Lead sponsor
Mitra RxDx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Timeline
2017 – 2019
U.S. locations
30
States / cities
Gilbert, Arizona • Aurora, Colorado • Norwich, Connecticut + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Oct 20, 2026, 10:36 PM EDT
Completed Phase 2 Interventional

CI-1040 in Treating Patients With Advanced Breast, Colon, Pancreatic, or Non-Small Cell Lung Cancer

NCT00033384
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Lung Cancer, Pancreatic Cancer
Interventions
CI-1040
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 12, 2013 · Synced Oct 20, 2026, 10:36 PM EDT
Completed No phase listed Observational

Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer

NCT00897793
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Prostate Cancer
Interventions
venipuncture, radiation therapy
Procedure · Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 12, 2013 · Synced Oct 20, 2026, 10:36 PM EDT
Completed Phase 2 Interventional Results available

ABI-007 (Nab-Paclitaxel) and Gemcitabine in Treating Women With Metastatic Breast Cancer

NCT00110084
View directory record Official record
Conditions
Breast Cancer
Interventions
Gemcitabine, Paclitaxel protein-bound particles for injectable suspension (albumin-bound)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
201
States / cities
Mobile, Alabama • Scottsdale, Arizona • Aurora, Colorado + 129 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2011 · Synced Oct 20, 2026, 10:36 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Metastatic Cancer

NCT00020267
View directory record Official record
Conditions
Lung Cancer, Adult Soft Tissue Sarcoma, Colorectal Cancer, Bone Cancer, Ovarian Sarcoma, Melanoma, Colon Cancer, Rectal Cancer, Breast Cancer, Eye Cancer, Uterine Sarcoma
Interventions
interleukin-2, MAGE-12 peptide vaccine, Montanide ISA-51
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Timeline
Started 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 20, 2026, 10:36 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy With or Without Cyclophosphamide and Doxorubicin in Women With Stage IV Breast Cancer

NCT00093834
View directory record Official record
Conditions
Breast Cancer
Interventions
allogeneic GM-CSF-secreting breast cancer vaccine, cyclophosphamide, doxorubicin hydrochloride
Biological · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 20, 2026, 10:36 PM EDT
Not listed No phase listed Observational

Biomarkers in Predicting Response to Tamoxifen and Letrozole in Postmenopausal Women With Primary Breast Cancer Treated on Clinical Trial CAN-NCIC-MA17

NCT00897065
View directory record Official record
Conditions
Breast Cancer
Interventions
microarray analysis, polymerase chain reaction, protein expression analysis, diagnostic laboratory biomarker analysis, fluorescent antibody technique, immunohistochemistry staining method, immunologic technique
Genetic · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
Female only
Enrollment
957 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Oct 20, 2026, 10:36 PM EDT
Completed Phase 2 Interventional Results available

Abraxane, Avastin, and Gemcitabine as First-Line Therapy for Patients With Metastatic Breast Cancer

NCT00503906
View directory record Official record
Conditions
Breast Cancer
Interventions
Avastin, Gemcitabine, Abraxane
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 12, 2017 · Synced Oct 20, 2026, 10:36 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer

NCT01828021
View directory record Official record
Conditions
Breast Cancer
Interventions
Margetuximab
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
6
States / cities
San Francisco, California • Stanford, California • Plantation, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 20, 2026, 10:36 PM EDT